Background: Overactive bladder (OAB) involves a complex set of symptoms with a lifetime prevalence of any symptom in 30% of women and 20% of men. Anticholinergic agents are associated with poor medication persistence in OAB treatment.
INTRODUCTION
Overactive bladder (OAB) is a condition involving a complex set of symptoms, including urinary incontinence, urgency, and frequency. OAB often goes undiagnosed and is associated with urinary tract infections, skin infections, and skin irritations, as well as a greater risk of falls. 1 A recent, large-scale US survey reported the lifetime prevalence for experiencing any symptoms at 30% in women and 20% in men. Moreover, 20% of women and almost 10% of men reported suffering symptoms "often." 2 Anticholinergic agents are frequently associated with poor rates of medication persistence when used for the treatment of patients with OAB, 3 and it is common for persistence to markedly decrease within the first 6 months of initiating treatment.
Beyond 1 year of anticholinergic medication use, patient persistence with treatment is reduced further. [4] [5] [6] [7] [8] In addition, increased adherence is the strongest predictor of decreased health care costs in the OAB population. A 10% increase in adherence to anticholinergic medication has been associated with a 5.6% reduction in total annual health care costs. 9 Although previous research has described the course of treatment discontinuation and treatment switching associated with the initial anticholinergic prescribed, there is a paucity of research exploring treatment patterns beyond use of the first anticholinergic. The objective of the present study was to evaluate the dynamics of treatment failure in OAB patients as related to their initial anticholinergic therapy and after failure of that initial treatment.
METHODS
This was an observational study that used a nonexperimental, retrospective cohort design. The methods were based on published articles with similar study designs and widely accepted research practices. 3, 6, 10 Patient records for this study were obtained from the IMS LifeLink Health Plan Claims Database (IMS Health, Danbury, Connecticut).
Data Source
The IMS LifeLink database contains information on 468 million unique patients in total from 4102 health plans across the United States and represents 16 million lives annually. The vast majority of plans included in the database are commercial (80%); a small percentage are identified as Medicaid (3%) or Medicare risk (1.7%) plans; and the remaining 15% are categorized as "other." For the present study, 3 component files encompassing medical, pharmacy, and eligibility data were obtained for men and women with a diagnosis of OAB between January 2005 and June 2010.
The medical file contains data on diagnostic and therapeutic services provided in both the inpatient and outpatient settings and uses International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes (diagnosis codes), Healthcare Common Procedure Coding System, and Current Procedural Technology, 4th Edition, codes. The pharmacy file contains data on prescription drugs dispensed at both retail and mail-order pharmacies, along with accompanying information regarding the characteristics of the drug dispensed, including the National Drug Code, quantity dispensed, and number of days supplied. Each claim includes the date a prescription was filled, the charged amount, and the amount paid. The eligibility file contains demographic data and periods of eligibility for each patient.
Inclusion Criteria
All men and women aged Z18 years were eligible for inclusion in the analytic data set. OAB was identified by a corresponding ICD-9-CM diagnosis code during the study period. ICD-9-CM codes identifying an OAB diagnosis included: 788.30, 788.31, 788.33-788.37, 788.39-788.43, 788.63, 596.51, 596.52, 596.55, and 596.59.
At least 1 pharmacy claim for an anticholinergic drug indicated for OAB (Table I) between July 2005 and June 2008 was required for inclusion in the final analytic data set. The first documentation of a prescription filled between these dates was defined as the index prescription, and the date of the fill was defined as the index date. In addition to a diagnosis of OAB and at least 1 prescription for an anticholinergic medication, patients were required to meet 3 other inclusion criteria: continuous enrollment for 6 months before the index date, a minimum of 24 months of follow-up from the index prescription date, and a "clean period" of 6 months immediately preceding the index date during which there was no documented prescription for an anticholinergic drug.
Outcomes and Analyses
Study outcomes were considered over 24 months after the index date. Those of interest included treatment failure, consisting of discontinuations and switches; treatment reinitiation; time to treatment failure; and medication adherence.
Treatment failure was defined as the proportion of patients who discontinued therapy or switched anticholinergic medications. To be considered a discontinuation, patients were required to have a gap of at least 45 days in therapy based on fill dates and days' supply. 3 Treatment switch was defined as the first filled prescription for any anticholinergic medication other than the previously prescribed medication within 45 days of the last filled prescription. This excluded any changes to a different dosage form within the same drug class (eg, from oxybutynin immediate release to oxybutynin extended release [ER]). The corresponding time to treatment failure was estimated as the number of days between the index date and the date of first medication switch or estimated discontinuation date.
Treatment reinitiation was defined as documentation of a filled prescription for any anticholinergic agent after a discontinuation period of Z45 days. The qualifying prescription could have been for the same medication as previously prescribed or a new/different anticholinergic medication.
Adherence to treatment was determined by using the medication possession ratio (MPR), defined as: (1) the sum of the total number of days a medication was supplied across anticholinergic claims except for the last pharmacy claim divided by (2) the total number of days from index to the fill date of the last pharmacy claim. The days' supply of the last pharmacy claim was excluded because it would artificially inflate compliance because it would result in perfect compliance for the last prescription. Thus, patients with only a single prescription claim were excluded from the analysis. Nonadherence was defined as an MPR o80%.
Descriptive analyses were conducted on the full cohort to characterize patients in terms of a range of factors, including age, sex, geographic region, index prescription year, index medication, plan type, medical history, and comorbidities. Summary statistics of the proportion of patients who failed, switched, and reinitiated anticholinergic therapy over 3, 6, 12, 18, and 24 months were estimated. The proportion of patients who demonstrated good (Z80%) adherence to medication was also estimated. Kaplan-Meier methods were used to estimate time to treatment failure over the 24-month period.
RESULTS
Records of 103,250 patients with a diagnosis of OAB met all inclusion criteria to form the study population. Patients had a mean (SD) age of 58.7 (15.7) years, and the majority of the study population was female and privately insured. Of the study cohort, 39.6% were aged 18 to 54 years, 27.3% were aged 55 to 64 years, and 33.1% were aged Z65 years. Men in this cohort were older than women (mean age, 62.8 vs 57.2 years) (P o 0.0001). Most patients initiated anticholinergic therapy in 2006 or 2007 (67%). One third of patients had a primary diagnosis other than OAB at the index date. The most commonly prescribed medication was tolterodine ER, with almost one half (42%) of patients receiving this as their index prescription (Table II) .
Treatment Failure
Almost all (92%) patients failed initial treatment with their index prescription ( Figure 1 ). Most treatment failures were associated with treatment discontinuation (86%) as opposed to a switch to another anticholinergic therapy (5.8%). In addition, 33% of patients filled only 1 prescription, suggesting early failure (within the first 30 days). The proportion of treatment failures was high across all primary diagnoses, ranging from 89.0% to 96.5%, and across the anticholinergic therapies, with 90% failing to meet treatment goals with tolterodine ER to 96% with oxybutynin transdermal (Table III) . Given this high rate of failure, outcomes were pooled across all drugs to estimate the overall impact of anticholinergic treatment for patients with OAB. The majority of patients (71.0%) failed treatment within 6 months of the index date, and the mean time to treatment failure was 159 (216) days ( Figure 2 , Table IV ). In an analysis of treatment discontinuation only, 66.9% of the study population had discontinued treatment at the end of 6 months, with this estimate increasing to 78.4% by the end of year 1 and to 85.9% at the end of year 2. More than one half (51.3%) had permanently discontinued anticholinergic treatment by the end of 2 years, with most discontinuations occurring in the first 6 months. Forty-eight percent of patients demonstrated appropriate adherence as determined by an MPR Z80%.
Switch Rate
Only 5.8% of the total cohort with a treatment gap r45 days switched their index anticholinergic over the 24-month period ( Table IV) . Most of the switching occurred within the first 3 months and remained relatively stable over the follow-up period. A large majority (81%) of patients who switched from their index anticholinergic therapy experienced treatment failure on a second-line anticholinergic therapy, 29% of whom tried a third agent and 71% who permanently discontinued all anticholinergic use. In a secondary analysis looking at any anticholinergic switch regardless of treatment gap, 21% of patients were found to have switched anticholinergic medication at least once during the study period. Patients received a mean of 1.3 (0.5) unique anticholinergic agents over the 24-month period. 
Treatment Reinitiation
The percentage of patients who reinitiated anticholinergic treatment after a treatment gap of at least 45 days was 34.6%. Approximately one fifth of patients (24.1%) restarted after 1 year, whereas 34.6% had restarted by the end of the 2 years (Table III) 
DISCUSSION
Current American Urological Association guidelines for OAB recommend anticholinergic drugs as first-line pharmacologic treatments in persons who fail to improve with behavioral therapies. 11 This study provides real-world data on patterns of anticholinergic use over 2 years in a large cohort of patients diagnosed with OAB. Over the course of 2 years, almost all patients experienced at least 1 treatment failure, and more than one half permanently discontinued treatment. At least one half of these failures and discontinuations occurred within the first 6 months after treatment initiation. Treatment failure was found to be high regardless of anticholinergic therapy choice, and adherence was suboptimal. Several studies have examined the rates of treatment failure involving anticholinergic therapies over a 6-to 12-month period. Depending on the study design, the rates of treatment failure range from 24.5% to 95%. 3, 6, 7, 10, 12 Studies that estimated treatment failure through patient surveys reported relatively low treatment failure rates (24.5%-45.0%) 13, 14 compared with claims analyses that typically reported 12-month rates 480%. 3, 6, 7, 10, 12 The low rates of discontinuation reported in patient surveys are not surprising because patients tend to overstate their adherence to medication. In addition, although surveys use patient self-report to analyze treatment failure for all anticholinergic agents, claims analyses have focused on treatment failure pertaining only to the first anticholinergic. In the present study, we used claims data to analyze treatment failure both for the index anticholinergic and overall. During the 24month follow-up period, almost all patients failed to improve with their index anticholinergic agent and approximately one half (51.3%) permanently discontinued all anticholinergic use.
One potential limitation of claims analyses of anticholinergic use is that intermittent or "as-needed" use is considered to be discontinued use of anticholinergic therapy, likely overestimating the actual discontinuation rate. Although we defined treatment Figure 2 . Treatment failure with anticholinergic medication. Treatment failure was defined as the proportion of patients who discontinued therapy (ie, treatment gap Z45 days) or who switched anticholinergic medications. All patients were required to have a minimum of 24 months' continuous eligibility from the index date. discontinuation as a treatment gap of at least 45 days between anticholinergic prescriptions, we analyzed the proportion of anticholinergic users who had a documented prescription refill occurring 445 days after their last prescription fill (ie, reinitiated use). Overall, one third of patients reinitiated therapy during the study period, with a majority reinitiating treatment with their index anticholinergic. Our findings are similar to those from an earlier study by D'Souza et al 3 ; however, rates of permanent discontinuation are somewhat higher in our study at 12 months (54% vs 45%), and rates of medication switches are almost one third the rate observed by D'Souza et al (5.8% vs 13%). Such differences may be explained by the definition of a treatment switch, which included within-class drug formulation changes in the study by D'Souza et al and the difference in patient populations that were studied. In their study, all patients prescribed tolterodine immediate release/ ER or oxybutynin immediate release/ER were eligible for the study, yielding a population that included 54% with a diagnosis of OAB. In contrast, our study required patients to have a diagnosis of OAB and a prescription for an OAB medication to be included. This finding suggests that anticholinergic therapies are used broadly for indications other than OAB. Nonetheless, a secondary analysis of any anticholinergic switch, regardless of treatment gap, found the switch rate to be much higher (21%).
Empirical studies of medication use have found persistence to OAB medications to be very low across medications that treat chronic conditions. A comparative analysis by Yeaw et al 10 assessed persistence with 6 chronic therapies: oral antidiabetic agents, angiotensin receptor blockers, statins, bisphosphonates, prostaglandins, and OAB medications. Persistence with OAB medications was found to be the lowest across the 6 drug classes. The 6-month persistence rate for OAB medications was 32% compared with 72% for oral antidiabetic agents.
Although there are differences in symptoms, adverse events, and patient-reported outcomes across anticholinergic medications, 15 failure and discontinuation rates are very high, irrespective of the choice of anticholinergic drug. Poor persistence with OAB medications can have a negative impact on healthrelated quality of life and increase the risk of medical sequelae, such as urinary tract infections, falls, and fractures. Benner et al 13 reported that dissatisfaction with treatment outcomes was the most common reason for anticholinergic discontinuation. A separate study that examined treatment goals in anticholinergic users found that less than one half of patients reportedly achieved their goal of symptom relief after oxybutynin therapy. 16 In addition, achievement of treatment goals was a strong predictor of treatment satisfaction. High reported rates of treatment failure and patient dissatisfaction with anticholinergic therapies reported in the literature 13, 14 suggest that patients are experiencing suboptimal therapy and symptom control. Effective management of OAB must be a provider-patient engagement that involves ongoing and open discussion to understand and monitor the patient's goals and expectations of treatment. Treatment options provided should be those that can help patients attain their goals. Licensed OAB therapies such as botulinium toxin A, sacral neuromodulation, and percutaneous tibial nerve stimulation should be offered as alternatives to patients who fail to meet their treatment goals with anticholinergic medications. Because the present analysis was based on claims data, clinical information such as symptom severity was not available to permit capture of this aspect, which may affect outcomes, including adherence and discontinuation. In addition, the reasons (eg, adverse events, limited efficacy) for treatment discontinuation, switching, and reinitiation of treatment cannot be determined by using these administrative data. This study nevertheless provides long-term data to suggest that most patients do not experience the intended benefits of anticholinergic medications, even when these agents are used as first-line therapy.
CONCLUSIONS
This study provides real-world data on treatment patterns over 2 years in a large cohort of patients diagnosed with OAB. We found high rates of anticholinergic treatment failure that started early in the course of treatment and resulted in permanent discontinuation by 50% of anticholinergic users by the end of 2 years. Despite the potential for better adherence with some anticholinergic agents, our study findings suggest that benefits of anticholinergic use in OAB are not being realized, and many patients end up without further medication therapy. and provided review and input to the analyses and manuscript throughout the preparation process. In addition, Dr. Corbell actively contributed to writing the Introduction and Discussion sections of the manuscript. Ms. Migliaccio-Walle led the manuscript preparation, provided oversight and guidance on the analyses, and participated in interpreting the results. Mr. Chaudhari was primarily responsible for conducting the data analyses and provided input and review to the manuscript.
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